SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------------
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 3)
LABORATORY CORPORATION OF AMERICA HOLDINGS
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $0.10 PAR VALUE
--------------------------------------------------------------------------------
(Title of Class of Securities)
5054OR 10 2
--------------------------------------------------------------------------------
(CUSIP Number)
Peter R. Douglas
Davis Polk & Wardwell
450 Lexington Avenue
New York, NY 10017
Tel. No.: (212) 450-4000
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 18, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1 (b)(3) or (4), check the following box |_|.
Note. This document is being electronically filed with the Commission
using the EDGAR system. See Rule 13d-1 (a) for other parties to whom
copies are to be sent.
*The remainder of this cover page should be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE>
Schedule 13D
--------------------------------------------------------------------------------
--------------------- -----------------
CUSIP No. 5054OR 10 2 13D Page 2 of 4 Pages
--------------------- -----------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Roche Holdings, Inc. 51-0304944
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e). [ ]
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER 11,352,537 shares of
SHARES Common Stock
BENEFICIALLY ---------------------------------------------------
OWNED BY 8 SHARED VOTING POWER N/A
EACH ---------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER 11,352,537 shares of
PERSON WITH Common Stock
---------------------------------------------------
10 SHARED DISPOSITIVE POWER N/A
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11,352,537 shares of Common Stock
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
32.71% of Common Stock
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO, HC
--------------------------------------------------------------------------------
2
<PAGE>
The following information amends and supplements the Schedule 13D dated
April 28, 1995, as previously amended (as so amended, the "Schedule 13D").
Item 1. Security and Issuer.
Item 1 of the Schedule 13D is hereby amended and restated in its entirety
as follows:
This statement relates to the Common Stock, par value $0.10 per share (the
"Common Stock") of Laboratory Corporation of America Holdings, a Delaware
corporation (the "Company"). The principal executive offices of the Company are
located at 358 South Main Street, Burlington, North Carolina 27215.
Item 4. Purpose of Transaction
Item 4 of the Schedule 13D is hereby amended by adding the following:
On October 18, 2000 Holdings sold 4 million shares of Common Stock in a
registered public offering resulting in proceeds to Holdings of $115.10 per
share. Prior to the offering Holdings owned 15,352,537 shares or 44.53% of the
Company's Common Stock. Immediately following the offering, Holdings' ownership
of the Company's Common Stock was approximately 32.71%.
The Company has filed a registration statement with the Securities and
Exchange Commission relating to the proposed offer and sale by Holdings of the
Company's Common Stock.
3
<PAGE>
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
accurate.
Dated: October 25, 2000
ROCHE HOLDINGS, INC.
By: /s/ Marcel Kohler
---------------------------
Name: Marcel Kohler
Title: Secretary
